Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx (NYSE AMERICAN: VNRX) is participating in a webinar hosted by Edison Group to discuss new data on the potential use of Nu.Q® NETs in sepsis management. The data, presented at ESICM LIVES 2024, includes three independent studies involving over 3000 patients and more than 14,000 patient samples. The webinar, scheduled for October 21, 2024, at 10:00 AM ET, will feature updates from Volition's Chief Medical Officer and Chief Commercial Officer.
The presentation will focus on the role of H3.1 nucleosomes in NETosis, the implications of elevated H3.1 levels in sepsis patients, and the potential of Nu.Q® NETs biomarker to predict organ failure. Volition's Nu.Q® NETs technology quantifies circulating H3.1 nucleosomes in the bloodstream, serving as a surrogate marker for Neutrophil Extracellular Traps (NETs). The company aims to develop simple, cost-effective blood tests for diagnosing and monitoring various diseases, including cancer, in both humans and animals.
VolitionRx (NYSE AMERICAN: VNRX) is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024. The session, titled 'NETs: Casting a new light on sepsis management', will feature experts presenting findings from large, independent studies on using Nu.Q® NETs to enhance sepsis management.
Professor Djillali Annane, chair of the symposium, highlights the potential of Nu.Q® NETs H3.1 assay in clinical practice for sepsis management. The symposium will explore the role of H3.1 nucleosomes in NETosis, the clinical utility of H3.1 in recent large-scale studies, and how Nu.Q® NETs biomarker could predict organ failure.
Nu.Q® NETs is Volition's technology that quantifies circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Elevated levels of NETs can lead to tissue damage, sepsis, organ failure, and death.
VolitionRx (NYSE AMERICAN: VNRX) has appointed Dr. Ethel Rubin as an independent director to its board, effective September 30, 2024. Dr. Rubin, with over 20 years of experience in the life sciences sector, will also serve on the Audit and Compensation Committees. Her extensive background includes leadership roles at BioFortis, CSA Medical, Medtronic, and currently as Head of Ventures at BioHealth Innovation.
Guy Innes, Interim Chair of Volition, highlighted Dr. Rubin's vast knowledge of the life sciences industry and her contribution to launching over 25 commercial products. Dr. Rubin expressed excitement about joining Volition, noting the potential of the company's Nu.Q® technology in both animal and human health sectors, particularly for early detection and monitoring of diseases like cancer and sepsis.
VolitionRx (NYSE AMERICAN: VNRX) hosted a Key Opinion Leader (KOL) roundtable in Paris to explore the potential of its Nu.Q® NETs technology in sepsis management. The event, chaired by Professor Djillali Annane, brought together leading sepsis experts worldwide. Discussions revealed that Nu.Q® NETs could potentially predict organ failure, such as acute kidney injury, in patients with infection, enhancing sepsis management.
Nu.Q® NETs quantifies circulating H3.1 nucleosomes in the bloodstream, a marker for Neutrophil Extracellular Traps (NETs). While NETs are important for immune response, elevated levels can lead to tissue damage and, in severe cases, sepsis and organ failure. Volition plans to share latest findings at an upcoming symposium at ESICM in Barcelona on October 7, 2024.
VolitionRx (NYSE AMERICAN: VNRX) announced its Q2 2024 financial results and business update. Key highlights include:
- Expanded access to Nu.Q® Vet Cancer Test to 17 countries
- Sold over 60,000 Nu.Q® Vet Cancer Tests in H1 2024, surpassing full-year 2023 sales
- Engaged in commercial discussions for potential licensing opportunities
- Q2 2024 revenue up 83% year-over-year at $396,000
- H1 2024 revenue up 55% year-over-year at $567,000
- Implemented cost reduction measures targeting $10 million in annualized savings
- Cash and cash equivalents of $6.0 million as of June 30, 2024
- Completed a $7 million registered direct offering with potential for additional $14.5 million
The company is focusing on securing its first licensing deal in the human space in H2 2024.
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering of up to $21.5 million. The offering includes 12,727,273 shares of common stock (or equivalents) and milestone-linked warrants at $0.55 per share. H.C. Wainwright & Co. is the exclusive placement agent. The initial gross proceeds are expected to be $7 million, with potential additional proceeds of $14.5 million if all warrants are exercised. The offering is set to close around August 12, 2024. Funds will be used for research, product development, clinical studies, commercialization, and working capital. The offering is made under a shelf registration statement filed with the SEC.
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Thursday, August 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2024 and provide a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, and Dr. Andrew Retter. Participants can join via phone or listen to a live audio webcast on Volition's investor relations website. A replay of the call will be available until August 29, 2024. This event provides an opportunity for investors and analysts to gain insights into Volition's recent performance and future outlook.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has enlisted PharmaVentures to provide strategic advice and support for licensing its oncology portfolio, including Nu.Q® Cancer and Capture-PCR™ technologies. The collaboration aims to secure licensing deals with industry leaders. Volition's technologies focus on simple, cost-effective blood-based assays to detect, guide treatment, and monitor cancer. Gael Forterre, Chief Commercial Officer of Volition, highlighted PharmaVentures' expertise in deal-making, while PharmaVentures' MD Adrian Dawkes expressed optimism about the potential of Volition's epigenetic technology to improve patient outcomes globally.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has issued a mid-year review before its Annual Meeting on July 2, 2024. The review highlights the expansion of the Nu.Q® Vet Cancer Test to 15 countries, ongoing commercial discussions with major players in liquid biopsy, IVD, sepsis, and oncology, and preparation for potential near-term licensing opportunities. CEO Cameron Reynolds emphasized significant progress in 2024, including supporting veterinary partners and advancing Nu.Q® NETs for sepsis, Nu.Q® Lung Cancer, and Capture-PCR™ technologies toward licensing. With substantial study data nearing readiness, Volition aims to negotiate its first human-space licensing deal in the second half of 2024.
RedChip Companies will air interviews with Nexalin Technology (Nasdaq:NXL) and VolitionRX (NYSE American:VNRX) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, June 15, at 7 p.m. ET. Nexalin's CEO, Mark White, discusses their non-invasive neurostimulation technology for mental health conditions like insomnia, PTSD, and traumatic brain injuries. Volition's CEO, Cameron Reynolds, highlights their epigenetic markers for diagnostics, focusing on cancer and sepsis. Volition aims for cash flow neutrality by 2025 through non-dilutive funding, revenue growth, and cost reduction.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
